Recently, Omicron, a covid-19 virus variant found in South Africa, has attracted close attention from the who because of more variation and faster transmission.
At present, Botswana, South Africa, Belgium, Israel and many other countries and regions have identified Omicron variants. Global health events are still complex and uncertain.
Therefore, under the background of the new number of confirmed cases in the world, in addition to vaccine prevention, covid-19 specific drugs can significantly reduce the hospitalization rate and mortality, and have the advantages of low cost and high clinical accessibility. Covid-19 specific drugs are expected to become an important relay.
On November 16, Asymchem Laboratories (Tianjin) Co.Ltd(002821) announced that it had signed a large order of nearly $480 million, and then on November 30, Porton Pharma Solutions Ltd(300363) announced that it had received an order of $217 million. According to industry researchers, the order probably comes from covid-19 small molecule drugs.
With reference to the data we calculated in the previous covid-19 specific drug industry chain report (see the industry chain report library for details), under a conservative scenario, based on the recent data of 263 million confirmed cases, the market scale of covid-19 specific drug is US $27.818 billion, and then calculated according to the value of API accounting for 8% (usually 6.5% – 10%), it is expected to bring us $2.225 billion market space to API.
Moreover, due to the competitive advantage of China’s API industry chain in the world, the large volume of covid-19 specific drugs in the future will benefit China’s API enterprises with strong CMO / cdmo capacity. Today, let’s look at several enterprises that have advantages in API.
From the recent growth of participants in the industrial chain: in the first three quarters, only Apeloa Pharmaceutical Co.Ltd(000739) and Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) increased positively.
